huBC1-huIL12 fusion protein AS1409
Term · Oncology and biomedicine · MLC-T-ONC-014234
An immunoconjugate consisting of the anti-tumor cytokine interleukin-12 (IL-12) fused to the tumor-targeting antibody BC1 with potential immunostimulatory and antineoplastic activities. The antibody moiety of huBC1-huIL12 fusion protein AS1409 binds to the human fibronectin splice variant ED-B, delivering IL-12 directly to the tumor vasculature; tumor vasculature-targeted IL-12 initiates localized immune cascade responses and exhibits cytotoxic and anti-angiogenic activity while minimizing the systemic side effects of IL-12. The human fibronectin splice variant ED-B is over-expressed in the extracellular matrix and blood vessels of tumor tissues.
| Identifier | MLC-T-ONC-014234 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-014234",
"term": "huBC1-huIL12 fusion protein AS1409",
"field": "Oncology and biomedicine",
"definition": "An immunoconjugate consisting of the anti-tumor cytokine interleukin-12 (IL-12) fused to the tumor-targeting antibody BC1 with potential immunostimulatory and antineoplastic activities. The antibody moiety of huBC1-huIL12 fusion protein AS1409 binds to the human fibronectin splice variant ED-B, delivering IL-12 directly to the tumor vasculature; tumor vasculature-targeted IL-12 initiates localized immune cascade responses and exhibits cytotoxic and anti-angiogenic activity while minimizing the systemic side effects of IL-12. The human fibronectin splice variant ED-B is over-expressed in the extracellular matrix and blood vessels of tumor tissues.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/hubc1-huil12-fusion-protein-as1409/"
}
Record 8,722 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.